Beta-NGF Informations sur la molécule
Molecule Name
Nerve growth factor
Alias de la molécule
NGF,NGFB,Beta-NGF,HSAN5,MGC161426,MGC161428
Drug Development Progress
Nombre de médicaments cliniques14
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéeNDA/BLA
Alias de la cible
Nerve Growth Factor
Contexte de la molécule
Nerve growth factor beta (beta-NGF) is a neurotrophic factor that plays critical role in the development and maintenance of sensory and sympathetic neurons. The active form of human beta-NGF is is a noncovalently disulfide-linked homodimer, which is secreted and signals through the low affinity nerve growth factor receptor (LNGFR) and the tropomyosin receptor kinase A (TrkA) to activate PI3K, Ras, and PLC signaling pathways.
Beta-NGF Liste de produits
You Have Viewed 0 Of 0 Results
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| RGN-259 | RGN-457; RGN-352; RGN-259; RGN-137; Tβ4; TB4; GBT-101; GBT-201; Thymosin beta 4-16-38; TB4 16-38; Thymosin beta4; Thymosin B4; Fx peptide | Phase 3 Clinical | National Institutes Of Health | Diabetes Mellitus; Dry Eye Syndromes; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica; Epidermolysis Bullosa, Junctional; Graft vs Host Disease; Keratitis; Myocardial Infarction; Myocardial Ischemia; Pressure Ulcer; Sjogren's Syndrome; ST Elevation Myocardial Infarction; Varicose Ulcer; Xerophthalmia | Details |
| Fasinumab | SAR-164877; MT-5547; R-475; REGN-475 | Phase 3 Clinical | Regeneron Pharmaceuticals Inc | Abdominal Pain; Back Pain; Low Back Pain; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Sciatica | Details |
| SSS-40 | SSS-40; SSS-40-anti-NGF Ab; SSS40 anti-NGF Ab | Phase 2 Clinical | 3sbio Inc | Bone Neoplasms; Cancer Pain; Osteoarthritis | Details |
| SHR-2017 | SHR-2017; SHR2017 | Phase 2 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Bone metastases; Multiple Myeloma; Osteoporosis; Solid tumours | Details |
| Antibodies to humanized nerve growth factor(Shenyang Sunshine Pharmaceutical) | Phase 2 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Bone metastases; Cancer Pain | Details | |
| EP-9001A | EP-9001A | Phase 2 Clinical | Chengdu Youluo Biotechnology Co Ltd | Bone metastases; Cancer Pain; Pain | Details |
| DS-002 | DS-002 | Phase 2 Clinical | Dartsbio Pharmaceuticals Ltd | Cancer Pain; Pain | Details |
| Atinumab | NG-101; ATI-355 | Phase 2 Clinical | Novartis Pharma Ag | Diabetic Gastroparesis; Gastroparesis; Spinal Cord Injuries | Details |
| Luvagrobart | AK-115 | Phase 1 Clinical | Cancer Pain; Pain | Details | |
| 4B03-04 | 4B03-04 | Phase 1 Clinical | Fubei Biomedical Technology (Beijing) Co Ltd | Osteoarthritis | Details |
| DS-010 | DS010; DS-010 | Phase 1 Clinical | Dartsbio Pharmaceuticals Ltd | Cachexia | Details |
| TNM-009 | TNM-009; TNM009 | Phase 1 Clinical | Zhuhai Trinomab Pharmaceutical Co Ltd | Cancer Pain; Pain | Details |
| SMR-7694 | SMR-7694; SMR7694 | Phase 1 Clinical | Sinobioway Biomedicine Co Ltd | Osteoarthritis | Details |
| Neuroregenerative agents (iNtRON Biotechnology) | Clinical | Intron Biotechnology | Nervous System Diseases | Details |